Cardiac I/R injury
We used established methods to assess I/R injury.
1 Rats were anesthetized with pentobarbitone sodium (60 mg/kg; i.p.), followed by administration of atropine (1 mg/kg; s.c.) and lignocaine (5 mg/kg; s.c.). A tracheotomy was performed and rats were ventilated with room air on a rodent ventilator (Model 7025; Ugo Basile, Comerio, VA, Italy). Stroke volume was set at 11 mL/kg and stroke rate at 40 breaths/min. Following cannulation of the right jugular vein, the left carotid artery was cannulated for continuous monitoring of heart rate, and phasic and mean arterial pressure via a Millar pressure catheter (SPR-407; Millar Instruments, Houston, TX, USA) connected to a PowerLab data acquisition system (Chart 5, v5.5.6; ADInstruments). Rats were subjected to thoracotomy at the 4th intercostal space to expose the heart. The LAD coronary artery was snared and blood flow occluded. After 30 min of ischemia, the ligature was released and blood flow restored. After 2 h reperfusion, the LAD coronary artery was re-occluded and 1 mL of 5% Evans blue dye injected intravenously to stain the perfused myocardium blue. When Evans blue staining of tissues was complete, the heart was removed and rinsed of excess dye. The left ventricle (LV) was then sliced transversely into 2-mm slices, photographed, and stained with 1% 2,3,5-triphenyltetrazolium chloride at 37°C for 15 min. The LV slices were then fixed in 10% formalin solution at room temperature overnight before repeat photography. Areas at risk (AAR) and infarct sizes were measured by planimetry (ImageJ, NIH, USA) for both sides of each slice. Animals with a mean arterial pressure <50 mmHg or those that exhibited prolonged arrhythmia during I/R injury were excluded from the study.
Measurement of AAR and infarct size
Each of the LV slices was weighed. The endpoint of cardioprotection was measured by infarct size as a ratio to AAR. The infarct size was calculated as described elsewhere. 2 Briefly, the total area, AAR and infarcted area for both sides of each slice were averaged, and the weights of the AAR and the infarcted area for each slice were calculated from these averaged values. The ratio of infarct size to AAR was calculated from the sum of these weights and expressed as a percentage of AAR.
Measurement of angiotensin and bradykinin peptides in heart and blood Angiotensin and bradykinin peptides were measured in heart and blood of female SpragueDawley rats treated with vehicle, aliskiren (10 mg/kg/day; s.c. minipump), valsartan (30 mg/kg/day; p.o.), or the combination of aliskiren and valsartan. After 4 weeks treatment, the 12-week old rats were anesthetized with a mixture of ketamine (75 mg/kg; i.p.) and xylazine (10 mg/kg; i.p.). The carotid artery was cannulated and blood samples (2 mL) were collected into 10 mL of 4 mol/L guanidine thiocyanate for measurement of angiotensin and bradykinin peptides. The cardiac ventricles were excised, rapidly rinsed free of blood with 0.9% saline and homogenized immediately in 10 mL of 4 mol/L guanidine thiocyanate. Blood and tissue homogenates were adjusted to 0.1% trifluoroacetic acid, centrifuged at 5020 g at room temperature for 15 min, and then processed as described previously. 3 Briefly, the supernatant from each homogenate was extracted on a Sep-Pak C 18 cartridge (Waters, Milford, MA, USA) before acetylation, piperidine treatment and high performance liquid chromatography. [3] [4] [5] [6] Concentrations of angiotensin (Ang) I, AngII, bradykinin (BK)-(1-9) and its metabolite BK-(1-7) were measured by N-terminal-directed radioimmunoassays. 4, 5 Peptide data were corrected for recovery as reported previously. [3] [4] [5] [6] Statistical analysis Data are expressed as means ± SEM. The significance of differences in systolic blood pressure (SBP), body weight and mean arterial blood pressure (MAP) was analyzed by twoway repeated-measures analysis of variance (ANOVA). The effects of aliskiren, valsartan and their combination on myocardial infarct size were analyzed by one-way ANOVA, and comparisons of the effects of treatment with vehicle were evaluated using Dunnett's test. The effects of icatibant and PD123319 were analyzed separately for each treatment group using Student's t-test. For the purpose of statistical calculations, peptide levels below the minimum detectable level were taken as half the minimum detectable amount. All peptide concentrations were logarithmically transformed prior to statistical analysis (ANOVA, posthoc Dunnett's test) because of a skewed distribution. All statistical analyses were performed using IBM SPSS Statistics (Version 21.0. Armonk, NY) and two-tailed P <0.05 was considered significant. Table S1 . Mean arterial blood pressure of anesthetized rats during cardiac I/R injury Prior to I/R, female Sprague-Dawley rats were administered vehicle, aliskiren (10 mg/kg/day) or valsartan (30 mg/kg/day), alone or in combination, for 4 weeks in: (i) the absence of an inhibitor; (ii) the presence of the B 2 receptor antagonist icatibant (0.5 mg/kg/day); or (iii) the presence of the AT 2 receptor antagonist PD123319 (30 mg/kg/day). Data represent means ± SEM (n = 7-13). No significant differences were detected between any of the treatment groups (two-way repeated-measures ANOVA, comparisons against respective vehicle, vehicle + icatibant or vehicle + PD123319 groups). Female Sprague-Dawley rats were administered vehicle, aliskiren (10 mg/kg/day) or valsartan (30 mg/kg/day), alone or in combination, for 4 weeks in: (i) the absence of an inhibitor; (ii) the presence of the B 2 receptor antagonist icatibant (0.5 mg/kg/day); or (iii) the presence of the AT 2 receptor antagonist PD123319 (30 mg/kg/day). Data represent means ± SEM (n = 7-13). Body weight (adjusted for minipump weights) increased over Weeks 1-4, with no effect of treatment (two-way repeated-measures ANOVA, comparisons against respective respective vehicle, vehicle + icatibant or vehicle + PD123319 groups). Aliskiren + valsartan + PD123319 199 ± 4 232 ± 6 251 ± 6 257 ± 5Table S3 . Heart weight and heart weight/body weight ratio of Sprague-Dawley rats Female Sprague-Dawley rats were administered vehicle, aliskiren (10 mg/kg/day) or valsartan (30 mg/kg/day), alone or in combination, for 4 weeks in: (i) the absence of an inhibitor; (ii) the presence of the B 2 receptor antagonist icatibant (0.5 mg/kg/day); or (iii) the presence of the AT 2 receptor antagonist PD123319 (30 mg/kg/day). Data represent means ± SEM (n = 7-13). †P<0.05, ‡ P<0.01 compared with vehicle + PD123319 (one-way ANOVA). Figure S4 . Effect of short-term administration of aliskiren on cardiac ischemia-reperfusion injury, expressed as the ratio of infarct size to area at risk (A); blood AngI (B), and AngII (C) peptide levels in female Sprague-Dawley rats administered 1 mg/kg i.v. bolus 5 min before occlusion followed by an infusion 10 µg/kg/min i.v. during ischemia and reperfusion. Data represent means ± SEM (n = 9-11). ***P<0.001 compared with vehicle (Student's t-test).
Mean arterial pressure (mmHg)
Treatment group During ischemia 30 min reperfusion 1 h reperfusion 1.5 h reperfusion 2 h reperfusion Vehicle 80 ± 6 81 ± 6 80 ± 6 78 ± 5 75 ± 5 Aliskiren 82 ± 5 84 ± 5 85 ± 5 75 ± 4 78 ± 4 Valsartan 80 ± 4 79 ± 4 79 ± 4 74 ± 4 71 ±
